FDA Brief

Warning letters Drugs

FDA warning letter to

Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

High riskIssued Nov 3Posted Nov 10Center for Drug Evaluation and Research (CDER)

FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

What happened

FDA reviewed records Nanjing Hanxin submitted after a Nov. 18, 2025 request and later correspondence. It found the quality unit failed to qualify suppliers of critical raw materials, records for an active pharmaceutical ingredient (API) were missing, and listed APIs included one not allowed for human drug compounding. FDA placed all drugs offered for import from the firm on Import Alert 66-40 (an FDA import detention list) on June 22, 2026.

What FDA found

  1. The quality unit did not ensure current good manufacturing practice (CGMP) compliance and failed to adequately qualify suppliers of critical raw materials.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. Supplier oversight was deficient; the firm qualified a supplier whose drugs FDA found adulterated (not meeting legal quality standards) and placed on Import Alert 66-40.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. FDA is concerned that naming the firm rather than the actual manufacturer of an API may have been an attempt to avoid import safeguards.

  4. The firm did not provide records about manufacture of an API at its facility and later said production moved to a subsidiary after November 2025.

    FD&C Act section 704(a)(4)
  5. The firm listed APIs not referenced in its records response, including one FDA says is not an API permissible for human drug compounding under sections 503A or 503B.

    FD&C Act sections 503A and 503B

What FDA wants

FDA tells Nanjing Hanxin to respond in writing within 15 business days of receipt with a corrective-action plan for supplier qualification and quality-unit oversight, stability and retest-date data, a three-year list of drugs and suppliers, and customer notifications for lots from noncompliant suppliers.

Who should pay attention

  • drugmakers that use Nanjing Hanxin APIs
  • sterile drug manufacturers and compounding operations sourcing these APIs
  • distributors and brands buying APIs from Chinese suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  2. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  3. Happy Farm Botanicals, Inc.

    Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.

    High risk
  4. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk